U.S. Patent 6,749,868 covers submicron particles of substantially water-insoluble drugs coated with protein and surrounded by associated free protein. The broadest commercial relevance is claim 12, which expressly covers paclitaxel particles coated with albumin. The patent underpinned the formulation technology used in Abraxane, but its listed U.S. patent term ended December 12, 2021, including patent-term extension. It is no longer a current U.S. barrier to an otherwise approvable albumin-bound paclitaxel product. [1][2]
U.S. Patent 6,749,868: Scope, Claims, Expiration, and Patent Landscape for Protein-Coated Drug Nanoparticles
What does U.S. Patent 6,749,868 protect?
U.S. Patent 6,749,868 protects a drug-delivery architecture rather than a particular therapeutic indication. Its independent claims require:
- A substantially water-insoluble pharmacologically active agent.
- Particles with an average diameter no greater than about 1 micron.
- A protein coating around the particles.
- Free protein associated with the protein coating.
- A portion of the drug contained within the protein coating.
- A portion of the drug associated with the free protein.
Claim 1 covers the drug-delivery system. Claim 7 covers the corresponding "bioprotected particles" as a composition of matter. The claims are directed to the physical organization of the drug and protein, not merely to the presence of albumin in a formulation.
The central inventive concept is a protein-associated, submicron drug particle designed to improve aqueous dispersion and biological handling of a poorly water-soluble active pharmaceutical ingredient. The claims encompass particles suspended in an aqueous vehicle, but the aqueous suspension limitation appears only in dependent claim 6.
What are the key claim limitations?
| Claim element |
Claims affected |
Scope significance |
| Substantially water-insoluble active agent |
1, 7 and dependents |
Excludes ordinary water-soluble drug formulations |
| Particle size no greater than about 1 micron |
1 and 7 |
Core submicron limitation |
| Less than 200 nm |
2, 8 |
Narrower nanoparticle embodiment |
| Protein coating |
1, 7 |
Required structural element |
| Free protein associated with coating |
1, 7 |
Distinguishes the claimed system from a bare coated particle |
| Drug partly within coating and partly associated with free protein |
1, 7 |
Important infringement and claim-construction limitation |
| Sterile filtration |
3, 9 |
Covers a sterile-filtered product, but only in dependent claims |
| Amorphous or crystalline particles |
4, 10 |
Covers both solid-state categories |
| Substantially amorphous particles |
5, 11 |
Narrower solid-state limitation |
| Albumin-coated paclitaxel |
12 |
Directly covers the Abraxane-type formulation |
| Antineoplastic, anesthetic or hormone |
13, 18 |
Defines broad therapeutic classes |
| Taxane |
14, 19 |
Covers paclitaxel-class embodiments |
| Propofol |
15, 20 |
Specific anesthetic embodiment |
| Thyroid hormone |
16, 21 |
Specific hormone embodiment |
| Non-crystalline active agent |
17 |
Alternative solid-state limitation |
How broad are the independent claims in Patent 6,749,868?
Claims 1 and 7 are broad within the defined particle technology. They are not limited to paclitaxel, albumin, oncology, intravenous administration, or a named commercial product.
Claim 1 covers a drug-delivery system. Claim 7 covers the particles themselves. This two-track structure increases the patent's theoretical reach because a product may potentially be analyzed as both a finished delivery system and a particle composition.
The claims do not require:
- A specific drug concentration.
- A specific albumin-to-drug ratio.
- A particular manufacturing solvent.
- A named milling, homogenization, emulsification, or precipitation process.
- A specific dosage regimen.
- A specific cancer indication.
- Intravenous administration.
- A particular container or excipient.
- A particular release profile.
The absence of these limitations gives the claims broad subject-matter coverage. It also creates potential validity and infringement disputes because the claim terms depend heavily on analytical evidence concerning particle structure, protein association, and drug distribution.
What does "free protein associated therewith" mean?
The phrase is a critical limitation. It requires more than protein forming a surface layer on the drug particle. The claims also require free protein associated with that coating. The claimed drug is distributed in two locations: partly within the protein coating and partly associated with the surrounding free protein.
A product containing albumin only as a conventional excipient may not satisfy this limitation. Conversely, a product with albumin physically associated with the particle surface and carrying a portion of the drug may present a stronger literal-infringement case.
The practical dispute would focus on analytical characterization, including particle-size measurement, protein binding, drug partitioning, surface composition, and the distinction between bound protein and free associated protein.
What products are most directly covered by the patent?
The clearest commercial embodiment is albumin-bound paclitaxel in the submicron particle format used for Abraxane. Claim 12 specifically recites paclitaxel as the active agent and albumin as the protein.
The patent also reaches other drug classes through claims 13 to 21. The claim set identifies:
- Taxanes and other antineoplastic agents.
- Propofol and related anesthetic applications.
- Thyroid hormones.
- Amorphous or crystalline drug particles.
- Sterile-filtered sub-200-nanometer systems.
- Aqueous suspensions.
Claim 12 is narrower than claim 1 because it requires both paclitaxel and albumin. It is also commercially important because it maps directly onto the best-known product associated with the patent family.
What is the Orange Book status and expiration date?
The U.S. Food and Drug Administration listed U.S. Patent 6,749,868 in the Orange Book for Abraxane, the albumin-bound paclitaxel product approved under NDA 021660. The listed patent expiration date was December 12, 2021. [2][3]
| Item |
Data |
| Patent |
U.S. 6,749,868 |
| Title |
Biocompatible protein-coated particles |
| Issue date |
June 15, 2004 |
| Principal technology |
Protein-coated submicron particles |
| Commercial product association |
Abraxane, paclitaxel protein-bound particles |
| Orange Book role |
Listed patent for Abraxane |
| Listed expiration |
December 12, 2021 |
| Current status |
Expired in the United States |
The expiration date reflects the effective patent term reported for the patent. The patent was associated with the Abraxane regulatory exclusivity and patent framework, but expiration of the patent did not itself determine all regulatory exclusivity periods applicable to the product.
The patent should therefore be treated as historical prior art and as part of the prosecution and litigation record, not as a live U.S. exclusivity right.
When did Abraxane lose exclusivity?
Abraxane's market protection ended in stages rather than on a single date.
The product received FDA approval in October 2005. Its principal formulation patent, U.S. 6,749,868, reached its listed expiration on December 12, 2021. Generic competition then entered the market through abbreviated new drug application pathways after FDA approval of competing paclitaxel protein-bound particle products.
| Milestone |
Date or period |
| FDA approval of Abraxane |
October 2005 |
| Patent 6,749,868 issued |
June 15, 2004 |
| Patent 6,749,868 listed expiration |
December 12, 2021 |
| Generic albumin-bound paclitaxel competition |
Began after later FDA approvals |
| Current patent position |
No enforceable term under Patent 6,749,868 |
Regulatory exclusivity, patent exclusivity, pediatric exclusivity, and litigation-related stays must be analyzed separately. Patent 6,749,868 no longer blocks launch by itself.
Which companies challenged the Abraxane patent estate?
Historical ANDA challenges to Abraxane involved generic-drug companies seeking approval for paclitaxel protein-bound particles. Public litigation and FDA records identify challenges involving companies including Actavis, Sandoz and Teva-related entities, depending on the product and procedural stage.
The principal legal issues included whether proposed generic products would infringe the protein-coated particle claims and whether the patent claims were valid and enforceable. The commercial importance of the disputes arose from the difficulty of designing around a formulation claim that was written around particle size, protein association and drug distribution rather than around a single manufacturing step.
The litigation record should be evaluated patent by patent. A challenge to U.S. 6,749,868 did not automatically resolve later patents covering manufacturing methods, dosing regimens, or other Abraxane-related subject matter.
What was the significance of Paragraph IV certifications?
An ANDA applicant may submit a Paragraph IV certification stating that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. The filing can trigger patent litigation and a statutory approval stay under the Hatch-Waxman Act.
For a product corresponding to Abraxane, the relevant risk analysis required comparison of:
- Particle-size distribution.
- Protein identity and concentration.
- Whether the protein was a coating or merely an excipient.
- Whether free protein was associated with the coated particle.
- Drug allocation between the coating and surrounding protein.
- Sterility and filtration.
- The proposed product's labeling and use.
Because Patent 6,749,868 has expired, a new Paragraph IV challenge to that patent would have no present blocking effect. Historical Paragraph IV cases remain relevant for understanding the claim scope and generic design strategies.
What formulation patents protect albumin-bound paclitaxel?
Patent 6,749,868 is the foundational composition patent most directly associated with the albumin-bound paclitaxel platform. The broader Abraxane estate also included later patents and applications directed to manufacturing, particle preparation, formulation parameters, administration and clinical use.
A freedom-to-operate review should not stop with the 6,749,868 patent. Relevant categories include:
| Patent category |
Typical subject matter |
Relevance after 6,749,868 expiration |
| Core composition |
Protein-coated drug particles |
Historical; 6,749,868 expired |
| Manufacturing |
Homogenization, solvent removal, particle formation |
Potentially relevant if unexpired |
| Formulation |
Concentration, excipients, reconstitution and stability |
Product-specific |
| Method of use |
Cancer treatment and dosing schedules |
May remain relevant depending on claim and term |
| Process controls |
Sterility, filtration and particle-size controls |
May create manufacturing barriers |
| Brand-specific labeling |
Indications and dosing instructions |
Relevant to ANDA carve-outs and use codes |
Later patents cannot be assumed to have the same scope or expiration date as Patent 6,749,868. Each must be checked against the USPTO record, FDA Orange Book listing, terminal disclaimers, patent-term adjustment, patent-term extension and litigation history.
Does the patent cover manufacturing methods?
Patent 6,749,868 is principally a product and delivery-system patent. Its claims do not expressly require a particular process for producing the particles.
A generic manufacturer could therefore seek to avoid process patents while still needing to avoid the product limitations during the patent term. Before expiration, a noninfringing manufacturing route would not necessarily avoid infringement if the resulting particles satisfied claims 1 or 7.
After expiration, manufacturing freedom improves, but the technical specifications remain commercially important. A manufacturer still must achieve a reproducible particle-size distribution, acceptable protein association, sterility, stability and bioequivalence or equivalent clinical performance under the applicable FDA pathway.
How strong was the patent estate?
Technical strength
The patent was technically strong because it claimed a distinctive combination of:
- Poor water solubility.
- Submicron particle size.
- Protein coating.
- Free associated protein.
- Dual drug localization within and around the coating.
The combination was more difficult to design around than a simple claim to "paclitaxel plus albumin." A competitor could alter particle size, protein architecture, drug loading, or the physical state of the active ingredient, but each change could affect product performance and regulatory comparability.
Legal strength
The legal strength depended on proof of the structural and functional limitations. The broad language created potential challenges involving written description, enablement, indefiniteness, anticipation and obviousness. The commercial product association strengthened the practical significance of the claims, but commercial success alone does not establish validity.
The patent's current legal strength is zero as an exclusion right because the U.S. term has expired. Its continuing value is evidentiary and strategic: it remains relevant to prior-art analysis, patent-family review, invalidity arguments, and the design history of albumin-bound drug products.
What generic launch risks remain?
Patent 6,749,868 no longer creates a standalone launch block. Current launch risks for an albumin-bound paclitaxel product instead include:
- Unexpired continuation or improvement patents.
- Product-specific formulation patents.
- Method-of-use patents and labeling restrictions.
- FDA requirements for demonstrating pharmaceutical equivalence or therapeutic equivalence.
- Differences in particle-size distribution and protein association.
- Manufacturing reproducibility and sterile filtration.
- Commercial supply of high-quality paclitaxel and albumin.
- Patent rights outside the United States.
A product can avoid infringement of the expired patent and still face regulatory or commercial obstacles under later patents or a different FDA approval standard.
Is there biosimilar risk for Patent 6,749,868?
No conventional biosimilar pathway applies to paclitaxel protein-bound particles because paclitaxel is a small-molecule active ingredient. Abraxane competitors generally proceed through abbreviated new drug application or other small-molecule regulatory pathways, not under the Public Health Service Act biosimilar framework.
Albumin is a biological protein component of the formulation, but its presence does not convert the paclitaxel product into a biologic subject to biosimilar approval. The relevant competition is generic or follow-on drug competition, with product-specific FDA requirements.
What is the competitive landscape for albumin-bound paclitaxel?
The commercial market is shaped by three groups:
- The branded Abraxane product.
- FDA-approved generic paclitaxel protein-bound particle products.
- Alternative formulations of paclitaxel, including solvent-based products and other delivery technologies.
Generic competition can reduce price and increase hospital purchasing leverage. It may not produce full interchangeability if products differ in labeling, supply reliability, clinical data packages, or institutional contracting.
The formulation technology remains commercially relevant because albumin-bound paclitaxel avoids the Cremophor EL vehicle used in conventional solvent-based paclitaxel. That distinction affects administration practices, premedication requirements and product positioning, even after patent expiry.
What revenue exposure did the patent protect?
Abraxane generated substantial commercial revenue before generic competition. Celgene reported Abraxane sales of approximately $1.1 billion in 2018, and Bristol Myers Squibb reported the product as part of the Celgene portfolio after its 2019 acquisition. [4][5]
The economic exposure to Patent 6,749,868 was therefore significant during the branded period. The patent protected a formulation platform used across multiple approved indications, including metastatic breast cancer, non-small-cell lung cancer and pancreatic cancer. The patent's expiration changed the risk profile from patent-protected branded sales to price competition and volume erosion.
What geographic coverage does Patent 6,749,868 provide?
U.S. Patent 6,749,868 provides rights only in the United States. International protection depends on separate national patents and validated regional rights derived from the relevant patent family.
A global freedom-to-operate review must examine:
- European Patent Office family members.
- Canada.
- Japan.
- China.
- Australia.
- Latin American jurisdictions.
- Patent-term adjustments or extensions.
- National opposition, revocation and litigation records.
Expiration in the United States does not establish expiration elsewhere. The commercial impact of the U.S. patent was greatest in the U.S. market because the patent was listed in the FDA Orange Book and could support Hatch-Waxman litigation.
Key Takeaways
- U.S. Patent 6,749,868 covers submicron particles of poorly water-soluble drugs coated with protein and associated with free protein.
- Claims 1 and 7 are the core independent claims.
- Claim 12 specifically covers paclitaxel particles coated with albumin.
- The patent is broader than Abraxane and is not limited to oncology, paclitaxel, albumin or intravenous use.
- Critical limitations include particle size, protein coating, free associated protein and dual drug localization.
- The patent was listed in the Orange Book for Abraxane.
- Its listed U.S. expiration date was December 12, 2021.
- It no longer creates a current U.S. patent barrier to an albumin-bound paclitaxel product.
- Later formulation, manufacturing and method-of-use patents require separate analysis.
- Competition is generic rather than biosimilar because paclitaxel is a small-molecule drug.
- Historical Paragraph IV litigation remains relevant to claim construction and design-around strategy.
FAQs
Does Patent 6,749,868 cover only Abraxane?
No. The patent covers a broader class of protein-coated submicron particles containing substantially water-insoluble pharmacologically active agents. Abraxane is the most commercially important embodiment, but the claims also identify taxanes, propofol, thyroid hormones and other therapeutic classes.
Does a formulation with albumin automatically infringe the patent?
No. Albumin alone is insufficient. The product must satisfy the claimed particle size, protein-coating and free-protein association limitations, including the claimed distribution of drug within the coating and in association with free protein.
Can a generic use a different protein instead of albumin?
Potentially. Claim 12 requires albumin, but claims 1 and 7 are not limited to albumin. A non-albumin protein could still raise infringement issues if the other claim limitations are met.
Does the expired patent eliminate all Abraxane-related patent risk?
No. Expiration eliminates the blocking effect of Patent 6,749,868, but later patents may cover manufacturing processes, formulation parameters, administration methods or treatment regimens.
Are albumin-bound paclitaxel products biosimilars?
No. They are generally regulated as generic or follow-on small-molecule drug products rather than as biosimilars under the Public Health Service Act.
References
-
United States Patent and Trademark Office. (2004). Biocompatible protein-coated particles (U.S. Patent No. 6,749,868).
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2005). Abraxane prescribing information. FDA.
-
Celgene Corporation. (2019). 2018 annual report. Celgene Corporation.
-
Bristol Myers Squibb Company. (2020). 2019 annual report. Bristol Myers Squibb.
